Klimicin

Clindamycin, the active ingredient in Klimicin, is a lincosamide antibiotic presented as an injectable for intramuscular and intravenous use. It is indicated for the treatment of susceptible bacterial infections in patients who require parenteral therapy, such as skin and soft‑tissue infections, bone and joint infections, and intra‑abdominal infections caused by susceptible organisms.

GNH USA supplies Klimicin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Clindamycin is a lincosamide antibiotic that targets Gram‑positive and anaerobic bacteria in a variety of infection sites.

- Skin and soft‑tissue infections: resolves cellulitis, abscesses and wound infections caused by susceptible strains. - Bone and joint infections: treats osteomyelitis and septic arthritis when oral therapy is unsuitable. - Intra‑abdominal infections: effective against anaerobic peritonitis and intra‑abdominal abscesses. - Respiratory tract infections: used for severe community‑acquired pneumonia due to susceptible organisms. - Bacterial vaginosis: eradicates anaerobic flora responsible for the condition.